Taiwan Outcomes and Real-world Treatment Options for Chronic Obstructive Pulmonary Disease

Number of Participants With Moderate-to-severe Acute Exacerbation

Annualized Rate of Moderate-to-severe Exacerbation

Annualized Rate of Mild Exacerbation

Annualized Rate of Moderate Exacerbation

Annualized Rate of Severe Exacerbation

Incidence of Patients Escalating Therapy (From Single/Dual to Dual/Triple Therapy)

Percentage of Patients Receiving Dual Therapy Escalated to Triple Therapy or LAMA Escalated to Dual Therapy

Change From Baseline in Pulmonary Function After LABA+LAMA or LAMA Initiation Evaluating by Post-bronchodilator Forced Expiratory Volume in One Second (Post-FEV1) at 12 Months After Index Date

Change From Baseline in Pulmonary Function After LABA+LAMA or LAMA Initiation Evaluating by Post-bronchodilator Forced Volume Vital Capacity (Post-FVC) at 12 Months After Index Date

Change From Baseline in Pulmonary Function After LABA+LAMA or LAMA Initiation Evaluating by COPD Assessment Test (CAT) Score at 12 Months After Index Date

Change From Baseline in Pulmonary Function After LABA+LAMA or LAMA Initiation Evaluating by Modified Medical Research Council Dyspnea Scale (mMRC) at 12 Months After Index Date

Percentage of Patients Using Rescue Medications